Recognition of and steps to mitigate anxiety and fear of pain in injectable diabetes treatment
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Injectable treatments, such as glucagon-like peptide-1 receptor agonists and insulin, are options for the pharmacologic treatment of type 2 diabetes. Numerous barriers lead to delay in initiating injectable treatment, which, in turn, may lead to inadequate glycemic control and increased risk of diabetes-related complications, underscoring the need to understand and address these barriers. Barriers to the initiation of injectable therapy, strategies to mitigate barriers, and information about needle attributes and their relation to needle pain are reviewed on the basis of published literature retrieval and our clinical experience. Barriers to the initiation of injectable therapy originate from both patients and practitioners. Anxiety about and fear of injection-associated pain has been estimated to affect approximately 30%-50% of patients before the initiation of diabetes education interventions. Advances in needle design have minimized the pain associated with injections, and recent data suggest that actual pain and bleeding associated with various needle gauges (21-gauge to 31-gauge) are mild. Other barriers include concerns about the ability to handle injectable therapy, concerns about treatment side effects, and impacts on quality of life. Practitioners can help to mitigate barriers to injectable treatment for type 2 diabetes by understanding patient perceptions, improving education, and setting realistic expectations about therapy. Strategies for minimizing injection-associated fear and anxiety include a combination of assessment, appropriate needle selection, patient education, behavioral interventions, and monitoring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
The Prevalence of Comorbid Depression in Adults With Diabetes
Anderson, R. J., Freedland, K. E., Clouse, R. E., & Lustman, P. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.6.1069 · Cited by 3,926 · cited 1×
“…T2D are approximately two times more likely than patients without diabetes to have major depression, with an estimated prevalence of 20%–30%, 17,18 and depression has been associated with poor glycemic control ( P , 0.0001), 21 Thus, before initiating injectable therapy, practitioners should…”
BackgroundInfluentialInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Depression and poor glycemic control: a meta-analytic review of the literature.
Lustman, P. J., Anderson, R. J., Freedland, K. E., de Groot, M., Carney, R. M., & Clouse, R. E. (2000) · Diabetes Care · doi:10.2337/diacare.23.7.934 · Cited by 1,854
Depression and Diabetes Treatment Nonadherence: A Meta-Analysis
Gonzalez, J. S., Peyrot, M., McCarl, L. A., Collins, E. M., Serpa, L., Mimiaga, M. J., & Safren, S. A. (2008) · Diabetes Care · doi:10.2337/dc08-1341 · Cited by 1,060
Gill, H. S., & Prausnitz, M. R. (2007) · Journal of Diabetes Science and Technology · doi:10.1177/193229680700100517 · Cited by 164 · cited 2×
“Although patients may be mostly concerned with the length of the needle, needle gauge also may influence possible injection-associated pain.(25) In a study using automated needle insertions of varying gauge (23–32 gauge) into the abdomen and thigh, investigators evaluated the number of painful insertions in patients a…”
BackgroundHirsch, L., Gibney, M., Berube, J., & Manocchio, J. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600216 · Cited by 96 · cited 1×
“01).(34) When tested by insulin-taking patients in the home setting where they were informed that”
Method
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
“Second, the need for daily or weekly injections discourages some patients from initiating GLP-1 RAs [184].”
BackgroundPersonalized type 2 diabetes management: an update on recent advances and recommendations
Williams, D. M., Jones, H., & Stephens, J. W. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s331654 · Cited by 121
Commentary: Why Was Inhaled Insulin a Failure in the Market?
Oleck, J., Kassam, S., & Goldman, J. D. (2016) · Diabetes Spectrum · doi:10.2337/diaspect.29.3.180 · Cited by 84
Hamid, A., Vaduganathan, M., Oshunbade, A. A., Ayyalasomayajula, K. K., Kalogeropoulos, A. P., Lien, L. F., Shafi, T., Hall, M. E., & Butler, J. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000864 · Cited by 57
Metadata
- Authors
- Kruger, D., LaRue, S., & Estepa, P.
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2015-01
- Volume
- 8
- Pages
- 49
- ISSN
- 1178-7007 (ISSN-L)
- OpenAlex
- W2017222422
- Cited by
- 73
- References
- 8
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recognition of and steps to mitigate anxiety and fear of pain in injectable diabetes treatment. https://app.cochat.ai/papers/10.2147/dmso.s71923
- The paper
- Kruger, D., LaRue, S., & Estepa, P. (2015). Recognition of and steps to mitigate anxiety and fear of pain in injectable diabetes treatment. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. https://doi.org/10.2147/dmso.s71923
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.